CanadaApotex Inc. Apo‑Tiotropium capsules (tiotropium bromide monohydrate 18 mcg; DIN 02550865) are affected — affected lot numbers: LC87540, LC87541, LC87616, LC88196, LC88197, LC88316, LC88318, LC88319, LC89638, LC89639, LC89640, LC89641, LC89671, LC89681, LC89725 and LC89783. The lots were recalled because the particle size did not meet specifications. Verify whether your product is one of the affected lots, consult your healthcare provider before stopping use or for health concerns, contact the recalling firm with questions, and report any side effects or other safety complaints to Health Canada.
What's being recalled
Depth of recall: Retailers
Companies: Apotex Inc., 150 Signet Drive, Toronto ON, M9L 1T9.
How to identify it
Brand: Apotex Inc.; Product Name: Apo-Tiotropium capsule; Market Authorization: DIN 02550865; Dosage Form: Capsule; Strength: Tiotropium bromide monohydrate 18 mcg; Lot Number: LC87540 LC87541 LC87616 LC88196 LC88197 LC88316 LC88318 LC88319 LC89638 LC89639 LC89640 LC89641 LC89671 LC89681 LC89725 LC89783
The hazard
The particle size did not meet the specifications in the affected lots.
What to do
Verify if your product is affected.
Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
Contact the recalling firm if you have any questions about the recall.
Report any health product related side effects to Health Canada.
Report any other health product safety complaints to Health Canada.
The official notice
This page is a summary of the notice published by Health Canada, collected from Health Canada, CFIA and Transport Canada. Check the original before you act on it.
Read the official notice (opens in a new tab)